ASCO GU 2022

Neoadjuvant therapy in UTUC: Good options for selected patients

ADC in bladder cancer: defining the future!

Role of PARPi in urothelial cancer

PARPi in urothelial cancer: DFS advantage for the DDR+, OS data pending.

ADCs will be step-changing in urothelial cancers

Exciting data supports trimodality therapy

Follow-up data confirm OS benefit across subgroups

Ongoing immunotherapy innovation for mCRPC

ADC shape the therapy landscape in urothelial cancer

IO escalation results in improved response in met. TCC.

Mature data confirm efficacy of maintenance avelumab as standard of care

Patient selection for bladder preservation

Not practice changing, but hypothesis generating.

HER2 ERBB2 – entering precision oncology

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Triplet vs. doublet: Which patients should we consider?

Enza beyond progression? Practice changing or not?

Do we need testing? Which biomarkers are of relevance?

Theranostics – Presence and future: Vision, PSMAfore, PSMAAddition, TheraP

The future of genetic testing. Somatic vs. germline? International perspectives

Is biomarker development taking a back seat in prostate cancer?

The need for biomarker panels in biopsy decision making

Exciting new compound for mCRPC

Should we use arbiraterone and niraparib as 1st line treatment of mCRPC with BRCA1/2 mutation?

How to improve PSMA based radioligand therapy

Triplet-therapy as a novel treatment option

Should we use arbiraterone and olaparib as 1st line treatment of mCRPC?

Subgroup analyses confirm the importance of oral daily GnRH Antagonist - relugolix

New therapies and molecular targets in prostate cancer

Addition of darolutamide improves OS in met. hormone-sensitive PC

Where do PROpel and Magnitude agree?

PSMA and FDG PET as biomarkers for response to LuPSMA

Is the dual hormone-backbone the future?

The importance of conducting HCRA

PSA response correlates with OS and benefits in QoL

DARO in triplet therapy for CRPC

HRR testing: MAGNITUDE vs. PROpel

Is docetaxel still needed for hormone sensitive mCRPC?

PROpel & Magnitude: who wins the race?

PRESIDE indicates benefit of continuation ENZA + ADT

Thoughts on first line treatment options following ASCO GU 2022

Neoadjuvant IO+TKI Treatment: We need more data on efficient IO/TKI combinations

Treatment options following adjuvant PD1 Therapy: Uncertainty of choices!

Adjuvant PD1 Therapy confirms significant benefit for high-risk patients. An individual risk benefit assessment is required!

Consistent OS benefit confirmed. Consider overtreatment vs. undertreatment!

Nivo montoherapy followed by Nivi-Ipi resuce

CheckMate final OS Follow Up and health related QoL

Update in adjuvant therapy for kidney cancer

Adjuvant Pembroluzimab update in kidney cancer

Microbioma modification and checkpoint inhibition

Frontline treatment of metastatic kidney cancer

Neoadjuvant avelumab/axitinib - NeoAvAx

Data gap in 2nd line RCC: what’s new?

Update in neoadjuvant therapy for kidney cancer